Managed Healthcare

What does MFN pricing mean for formulary strategy, contracting & access? The data & expert perspectives are available to help you stay ahead. Explore what industry leaders are signaling for 2026: hubs.li/Q04gNG3K0 #DrugPricing #MostFavoredNation #ManagedCare

Here’s what managed care leaders should know about UnitedHealthcare's prior authorization changes cutting approvals 30% hubs.ly/Q04gHDxB0

Discover the top 10 trends redefining managed care in 2026, from AI to specialty drugs. See what’s shaping payer & provider decisions now. Sign in or share a few details to access: hubs.li/Q04gtghS0 #ManagedCare #HealthcareTrends

FDA Commissioner Marty Makary resigns after 13 months hubs.li/Q04glflX0

A look behind the scenes 🎬 If you missed the live session, the recording of our #SpecialtyPharmacy webinar is now available to watch at: hubs.li/Q04gj5St0 #HealthcarePolicy #DrugPricing #ManagedCare #FreeWebinar

What is the clinical impact of JAK inhibition in #Vitiligo? Seemal Desai, MD, FAAD, reviews TRuE-V trial data, repigmentation outcomes, and safety insights with ruxolitinib cream. Watch Now: hubs.li/Q04fYBD50 #Dermatology #ManagedCare

Last chance to join our #SpecialtyPharmacy debriefing today at 12pm EDT! Hear expert insights on rising spending, pricing leverage, distribution control & future market disruptors as revealed at Asembia's AXS26 Summit. Register now: hubs.li/Q04fNYqY0 #ManagedCare

#MultipleMyeloma makes up only 1.8% of cancer diagnoses but is the second most common #BloodCancer in the U.S. This video breaks down prevalence trends and the expanding treatment landscape, including #BispecificAntibodies and CAR T-cell therapy. Watch: hubs.li/Q04f4f8s0

Switching from finger sticks to CGM can change adherence, safety and long-term outcomes. In this episode, experts discuss how alerts, shared data and reduced burden help patients stay engaged and avoid dangerous highs and lows. hubs.li/Q04cLPVR0 #CGM #ManagedCare #Diabetes

One week away! Going live on May 7 to discuss #SpecialtyPharmacy's growth following Asembia's AXS26 Summit. Our expert panelists will address pricing pressures, access challenges & policy forces shaping the next wave of market disruption. Register now: hubs.li/Q04f2ssr0

IQVIA's Luke Greenwalt, MBA, a member of the MHE editorial advisory board, talked about the era of the mega-blockbuster at the general session that opened the second day of the Asembia special pharmacy summit in Las Vegas.

MHE is in Vegas covering Asembia's AXS26 Summit!

Our 2026 State of Pharmacy findings are now available. Check out the expert commentary and survey data that contextualize where the industry may be headed. Download the report here: hubs.li/Q04dxVtw0 #PharmacyStrategy #PharmacyLeadership #ManagedCare

In a recent Dutch study, skin cells actively helped the rabies virus multiply and pass into nearby nerve cells, explaining how even small bites or scratches, particularly from bats, can lead to infection. hubs.li/Q04dfZ140

Hear industry leaders unpack the economics behind #SpecialtyPharmacy growth, pricing control, access and distribution strategy. A must-attend post-Asembia debriefing for payer and pharmacy decision-makers. Save your seat for May 7: hubs.li/Q04dbnY40 #ManagedCare

#NSCLC care has evolved from #chemo to #immunotherapy. What gaps drove that shift, and what do five-year EMPOWER-Lung 3 results mean for care today? Watch the Between the Lines expert discussion: hubs.ly/Q04cNjpq0

UnitedHealth Group’s earnings call signals a shift in strategy across managed care. AI, Medicare Advantage, and cost pressures are all in focus. What comes next for payers and providers? Sign in or share a few details to access: hubs.li/Q04c-Nbf0

Exclusive look at 4 takeaways from UnitedHealth Group’s first quarter earnings call hubs.li/Q04c-z8K0

#SpecialtyPharmacy is reshaping #HealthcareEconomics. Learn about growth, pricing, access, distribution, policy disruption and what it all means for the future of pharmacy spending. Join us for an expert discussion on May 7 at 12 pm EDT: hubs.li/Q04cy_cM0

That’s a wrap on #AMCP2026 in Nashville! 🎸 🎶 From specialty drug dominance and GLP-1 growth to gene therapy challenges and pricing pressure, the annual meeting addressed how payers are navigating it all. Missed any of our coverage? Take a gander below: hubs.li/Q04cwPbk0